The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NSABP FC-13 (EMPIRE): A phase II platform study of cemiplimab monotherapy or cemiplimab-based combinations in patients with colorectal cancer and minimal residual disease (MRD) after definitive therapy.
 
Anwaar Saeed
Consulting or Advisory Role - Arcus therapeutics; Astellas Pharma; AstraZeneca; Autem therapeutics; Autem Therapeutics; BeOne therapeutics; Bristol-Myers Squibb; Exelixis; Pfizer; Regeneron; Replimune; Taiho Pharmaceutical; Xilio therapeutics
Research Funding - Actuate Therapeutics (Inst); Arcus therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeOne therapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Incyte (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Oxford biotherapeutics (Inst); Phanes Therapeutics (Inst); Replimune (Inst)
 
Greg Yothers
Consulting or Advisory Role - Orbus Therapeutics
 
Shannon Puhalla
Consulting or Advisory Role - Abbvie; AstraZeneca; Celldex; Eisai; Novartis; Pfizer; Puma Biotechnology
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Covance/Bayer (Inst); Incyte (Inst); Lilly (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - Roche/Genentech
 
Priya Rastogi
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Lilly
 
Tanner Freeman
No Relationships to Disclose
 
Melissa Mathias
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Frank Seebach
Employment - Regeneron
Leadership - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Norman Wolmark
Research Funding - Breast Cancer Research Foundation (Inst)
Travel, Accommodations, Expenses - American Surgical Association
 
Thomas George
Consulting or Advisory Role - Arbele; Avammune Therapeutics; BillionToOne; Exact Sciences; Genentech/Roche; Janssen Oncology; KAHR Medical; Nihon Medi-Physics; Summit Therapeutics
Research Funding - Amal Therapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BillionToOne (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Elicio Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Merck (Inst); OncoC4 (Inst); Regeneron (Inst); Seagen (Inst)